Siamab to Present Preclinical Data for ST1 Antibody Drug Conjugates at 2017 BIO International Convention

Siamab to Present Preclinical Data for ST1 Antibody Drug Conjugates at 2017 BIO International Convention
Siamab Therapeutics will present new preclinical data on the safety and efficacy of its flagship ST1 antibody drug conjugates program in ovarian cancer animal models at the 2017 BIO International Convention in San Diego, June 19–22. The presentation by Jeff Behrens, Siamab’s president and chief executive officer, will also cover the company’s overall research into tumor–associated carbohydrate antigens

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *